NEW HAVEN, Conn., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that is has been awarded approximately $2.0 million in eight federal grants under the Qualifying Therapeutic Discovery Project (QTDP) program.
